生物活性：Rimonabant-d10 is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Rimonabant-d10 相关抗体:
MRP2 Antibody
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量：473.85
Formula：C22H11D10Cl3N4O
CAS 号：929221-88-5
非标记 CAS：168273-06-1
中文名称：利莫那班-d10
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (535 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Leite, C.E., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61 217-224 (2009).
[3]. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL.
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies.
Neuropharmacology. 2012 Oct;63(5):905-15.
 [Content Brief]
[4]. Zhang B, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019 Jan 24;176(3):636-648.e13.
 [Content Brief]
[5]. Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268.
 [Content Brief]